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PENGKLONAN DAN ANALISIS PROMOTER ISOFORM KOLINA KINASE 
MANUSIA 
 
ABSTRAK 
 
Kolina kinase (CK) merupakan enzim pertama di dalam laluan CDP-kolina untuk 
biosintesis fosfatidilkolina dalam semua tisu haiwan. CK memfosforilasikan kolina 
kepada fosfokolina dengan kehadiran ATP dan Mg
2+
. Dalam manusia, enzim ini 
dikodkan oleh dua gen yang berbeza iaitu ckα dan ckβ yang menghasilkan sekurang-
kurangnya tiga isoform protein yang dikenali sebagai CKα1, CKα2 dan CKβ. CK 
memainkan peranan yang penting dalam sintesis fosfolipid, karsinogenesis dan 
distrofi otot serta kecacatan tulang. Kawasan promoter CK adalah penting dalam 
pengawalaturan ekspresi gen ck. Kajian ini melaporkan pengklonan promoter ckα 
dan ckβ manusia dan penggunaan satu system pelapor untuk menilai aktiviti 
promoter tersebut. Jujukan promoter ckα (2009 bp) and ckβ (2000 bp) manusia pada 
bahagian hulu gen masing-masing, telah diklonkan ke dalam vektor pelapor 
lusiferase tanpa promoter, pGL4.10[luc2]. Plasmid rekombinan ini ditransfeksikan 
bersama dengan vektor kawalan dalaman Renilla lusiferase, pGL4.73[hRluc/SV40] 
ke dalam sel adenokarsinoma payudara manusia, MCF-7. Aktiviti promoter diukur 
dengan menggunakan asai lusiferase. Pelbagai mutan penghapusan terminal-5’ juga 
telah dihasilkan melalui teknik PCR dan diklonkan ke dalam vektor pGL4.10[luc2] 
untuk mengenalpasti kawasan promoter ckα dan ckβ yang penting untuk transkripsi 
gen. Keputusan kajian menunjukkan bahawa faktor transkripsi ETS merupakan 
pengawalatur negatif yang penting terhadap promoter ckα manakala factor-faktor 
transkripsi ETS and GATA merupakan pengawalatur negatif yang penting terhadap 
aktiviti promoter ckβ. Untuk mengesahkan kepentingan ETS dan GATA terhadap 
 xvi 
 
pengawalaturan transkripsi gen ckβ, beberapa mutasi telah diperkenalkan pada tapak 
pelekatan ETS dan GATA di dalam promoter ckβ. Aktiviti promoter bagi binaan 
mutan didapati telah meningkat secara mendadak. Seterusnya, sel-sel MCF-7 yang 
ditransfeksikan dengan vektor pelapor promoter ckβ telah dirawat dengan forbol 12-
myristat 13-asetat (PMA) untuk meninjau peranan PMA dalam mengawaltur ekspresi 
gen ckβ melalui factor-faktor transkripsi ETS dan GATA. PMA merupakan pengaktif 
PKC. Pengaktifan PKC telah meningkatkan pengawalaturan negatif, ETS dan GATA 
dan akhirnya mengurangkan aktiviti transkripsi promoter ckβ.  Keputusan 
menunjukkan bahawa aktiviti promoter ckβ telah dikurangkan dengan ketara selepas 
dirawat dengan PMA. Oleh itu, kajian ini telah mengenal pasti bahawa faktor 
transkripsi ETS dan GATA merupakan represor yang penting dalam pengawalaturan 
transkripsi gen ckβ.  
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CLONING AND PROMOTER ANALYSIS OF HUMAN CHOLINE KINASE 
ISOFORMS 
 
ABSTRACT 
 
Choline kinase (CK) is the first enzyme in the CDP-choline pathway for the 
synthesis of phosphatidylcholine in all animal tissues. CK phosphorylates choline 
into phosphocholine in the presence of ATP and Mg
2+
. In humans, this enzyme is 
encoded by two separate genes, ckα and ckβ which produce at least three protein 
isoforms known as CKα1, CKα2 and CKβ. CK plays an important role in 
phospholipid synthesis, carcinogenesis and muscular dystrophy as well as bone 
deformities. The CK promoter region plays a significant role in the regulation of the 
ck gene expression. This study reports the cloning of ckα and ckβ promoters and the 
use of a reporter system for evaluating the promoter activity. Promoter sequences of 
human ckα (2009 bp) and ckβ (2000 bp), located upstream of their respective genes, 
were cloned into a promoterless luciferase reporter vector, pGL4.10[luc2]. The 
recombinant plasmid was co-transfected with Renilla luciferase internal control 
vector, pGL4.73[hRluc/SV40] into the human breast adenocarcinoma, MCF-7, cell 
line. Its promoter activity was measured using the luciferase assay. Various 5’-
terminal deletion mutants were constructed by PCR technique and cloned into 
pGL4.10[luc2] vector in order to identify the region of the ckα and ckβ promoters 
that are important for gene transcription. The results showed that the ETS 
transcription factor is a crucial negative regulator for the ckα promoter while ETS 
and GATA transcription factors are important negative regulators for the ckβ 
promoter activity. To confirm the importance of ETS and GATA on the regulation of 
ckβ gene transcription, several mutations were introduced to the ETS and GATA 
 xviii 
 
binding sites in ckβ promoter. The promoter activities of the mutant constructs were 
dramatically increased. Subsequently, MCF-7 cells transfected with ckβ promoter 
reporter vector were treated with phorbol 12-myristate 13-acetate (PMA) to explore 
the role of PMA in ckβ gene regulation via ETS and GATA transcription factors. 
PMA is the activator of PKC. The activation of PKC increases the binding of 
negative regulators, ETS and GATA and hence decreases the transcriptional activity 
of ckβ promoter. Results showed that the activity of the ckβ promoter was 
significantly reduced after treatment with PMA. Thus, this study has identified ETS 
and GATA transcription factors as the important repressors in the regulation of ckβ 
gene transcription.  
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CHAPTER 1.0 INTRODUCTION 
 
1.1 Structures and functions of phospholipids 
Phospholipids are the major structural components of membranes (Figure 1.1) 
(Campbell and Reece, 2002). In almost all cells, the structure is a phospholipid 
bilayer that surrounds and contains the cytoplasm (Silhavy et al., 2010). 
Phospholipids have only two fatty acid tails and the third hydroxyl group of glycerol 
is joined to a phosphate group and a simple organic molecule such as choline 
(Campbell and Reece, 2002). All phospholipids have hydrophobic and hydrophilic 
domains. The hydrophobic domain is composed largely of the hydrocarbon chains of 
fatty acids; the hydrophilic domain, called a polar head group, contains phosphate 
and other charged or polar group (McKee and McKee, 2003). Furthermore, several 
phospholipids are emulsifying agents and surface active agents (Kuroki and Voelker, 
1994) as they are amphipathic molecules (Metzler and Metzler, 2001). Phospholipids 
consist of two major types: phosphoglycerides (also known as glycerophospholipids) 
and sphingomyelins (also known as sphingolipids) (Newsholme and Leech, 2010).  
 
1.1.1 Phosphoglycerides 
Phosphoglycerides, which are derived from glycerol, are the most abundant types of 
phospholipids found in cell membrane. All phosphoglycerides are derived from sn-
glycerol-3-phosphate (L-Glycerol 3-phosphate). Two fatty acid chains are esteried to  
the first and second carbons of the glycerol molecule, denoted as positions C-1 and 
C-2, respectively. Saturated fatty acids normally occur at C-1 of glycerol while the 
fatty acid substituent at C-2 is normally unsaturated. The C-3 hydroxyl group of the 
glycerol backbone is esterified to form different phosphoglycerides. 
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Figure 1.1 The structure of plasma membrane. It is made up of phospholipid 
bilayer and proteins with different functions are embedded inside it 
(Henderson et al., 1990). 
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The phosphoglycerides are named and classified according to the hydroxyl is 
esterified to the phosphate group of the phosphatidate. Phosphatidate have four 
common subtituents, serine, ethanolamine, choline and inositol (Lodish et al., 2000; 
Berg et al., 2002; McKee and McKee, 2003; Plopper, 2011). The major classes of 
phosphoglycerides are shown in Table 1.1.  
 
1.1.1(a) Phosphatidic acid 
Phosphatidic acid (PA) is the simplest phosphoglyceride, it is also known as 1,2-
diacyl-sn-glycerol-3-phosphate. PA is progressively being recognized as a crucial 
lipid second messenger in animal systems as well as in plants (Munnik, 2001; 
Testerink et al., 2004). Hydrolysis of PA by the enzyme phosphatidate phosphatase 
yields diacylglycerols, which are the precursors for the biosynthesis of triglycerides, 
phosphatidylcholine and phosphatidylethanolamine via the Kennedy pathway 
(Athenstaedt and Daum, 1999; Kooijman et al., 2005). PA also has significant roles 
in cell signaling and metabolic regulation in all organisms. Surprisingly, recent 
findings have demonstrated that PA also has an unprecedented role as a pH biosensor 
by coupling changes in pH to intracellular signaling pathways (Young et al., 2010; 
Shin and Loewen, 2011). Several proteins, including protein kinase C and small G-
proteins are activated by this diacylglycerol (Yang and Kazanietz, 2007). 
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Table 1.1 Major types of phosphoglycerides (McKee and McKee, 2003) 
 
    
X Substituent 
Name of Phospholipid 
Name of X-OH Formula of X 
Water  
Choline  
 
 
Ethanolamine 
  
 
Serine 
 
 
Glycerol 
 
 
 
Phosphatidylglycerol 
 
 
 
Inositol 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Phosphatidic acid 
 
Phosphatidylcholine   
(lecithin) 
Phosphatidylethanolamine 
(cephalin) 
 
 
Phosphatidylserine 
 
 
 
 
 
Phosphatidylglycerol 
 
 
 
 
 
 
Diphosphatidylglycerol 
(cardiolipin) 
 
 
 
Phosphatidylinositol 
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1.1.1(b) Phosphatidylcholine 
Phosphatidylcholine (PC) (also known as lecithin) has choline bonded with 
phosphate group of the phosphatidate (Scholfield, 1981). The PC generally is the 
most abundant phospholipid class in a membrane, in both animal and plant. It 
amounts to almost 50% of the total constituents and is the key building block of 
membrane bilayers. Many prokaryotes lack PC, but it is estimated that more than 10% 
of bacteria possess PC (Sohlenkamp et al., 2003). In animal tissues, PC tends to exist 
mainly in the diacyl form. In mammals, it is well known that PC is found in 
lipoproteins, biliary lipid aggregates and lung surfactant (Kanno et al., 2007). PC is 
synthesized through two distinct enzymatic pathways, namely, the de novo CDP-
choline pathway and the methylation pathway (Walkey et al., 1998). The CDP-
choline pathway involves the conversion of choline to CDP-choline through a 
phosphorylcholine intermediate for condensation with diacylglycerol to produce PC. 
This enzymatic pathway is present in all cells. In the methylation pathway, PC is 
produced via sequential methylation of phophatidylethanolamine by 
phosphatidylethanolamie N-methyltransferase, which is expressed only in the liver 
cells (Fernandez-Murray and McMaster, 2005; Witola and Ben Mamoun, 2007). 
 
1.1.1(c) Phosphatidylethanolamine 
Phosphatidylethanolamine (PE) (also referred as cephalin), is the second most 
abundant phospholipid in animal and plant, and constitutes for more than 50% of the 
total phospholipid species in eukaryotic membranes (Gibellini and Smith, 2010). 20% 
of phospholipids in the liver are PE and as much as 45% in the brain. Higher 
proportions of PE are found in mitochondria than in other organelles (Vance, 2008). 
Besides being the major constituent of membrane, the PE is a zwitterionic 
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phospholipid that involves in a number of biological events, such as in the blood 
coagulation, blood pressure regulation, and in the visual process (Song et al., 2012). 
The PE is synthesized via the de novo CDP-ethanolamine pathway in which the final 
reaction occurs on the endoplasmic reticulum and nuclear envelope (Vance and 
Vance, 2009). 
 
1.1.1(d) Phosphatidylserine 
Phosphatidylserine (PS) (1,2-diacyl-sn-glycero-3-phospho-L-serine) (Gaus et al., 
2005) is a quantitatively minor membrane phospholipid that makes up to 10% of the 
total phospholipids of mammalian cell membranes (Yamaji-Hasegawa and 
Tsujimoto, 2006). The cytoplasmic leaflet of the plasma membrane is generally rich 
in PS (Kay and Grinstein, 2011). Any disruption on the asymmetric distribution of 
phospholipids will lead to the appearance of PS on the cell surface. The PS is known 
to play a central role in both apoptosis and blood coagulation (Chaurio et al., 2009). 
Furthermore, PS is a required cofactor for protein kinase C (Vance and Steenbergen, 
2005). 
 
1.1.1(e) Phosphatidylglycerol 
Phosphatidylglycerol (PG) is a ubiquitous lipid in biological membranes (Sakurai et 
al., 2007). The PG is found in bacteria, such as E.coli, which made up to 20% in 
bacterial membranes. It is also mainly presents in thylakoid membranes of 
chloroplasts, which perform specific roles in the photosynthetic process in 
cyanobacteria and higher plants (Henin et al., 2009; Wada and Murata, 2009). The 
PG is synthesized only in the mitochondria of non-photosynthetic eukaryotes such as 
Saccharomyces cerevisiae and it is used as a precursor for the biosynthesis of 
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cardiolipin (Hagio et al., 2002). The PG is the major end product of the Kennedy 
pathway. PG forms the bilayer of the inner membrane and the inner leaflet of the 
outer membrane (Lu et al., 2011). The PG is crucial for viability of wild-type cells 
not only because it is a major component of the inner membrane but it also plays 
important roles in the initiation of DNA replication of oriC and SecA-dependent 
protein translocation (Dowhan, 2009). 
 
1.1.1(f) Diphosphatidylglycerol 
Diphosphatidylglycerol (also known as cardiolipin, CL) is located and synthesized in 
the mitochondrial inner membrane (Schlame et al., 2000). It is exclusively present in 
membranes of bacteria and of mitochondria of eukaryotes, and hence is found in 
virtually all organisms of the three domains of life: eubacteria, archaebacteria and 
eukaryote (Schlame, 2008). Furthermore, CL is most abundantly found in human 
tissues especially those that are rich in mitochondria, such as heart, skeletal muscle 
and liver tissue (Lu et al., 2006). The CL interacts with a large number of 
mitochondrial proteins and effects functional activation of certain enzymes, 
especially those involve in oxidative phosphorylation and photo-phosphorylation that 
result in ATP production (Chen et al., 2006).  
 
1.1.1(g) Phosphatidylinositol 
Phosphatidylinositol (PI) can be phosphorylated to form phosphoinositide. PI 
participates in essential metabolic processes in animals through a number of 
metabolites (Kim et al., 2010). Phosphorylation of PI by a number of different 
kinases produces phosphatidylinositol 4-phosphate (PIP) and phosphatidylinositol 
4,5-biphosphate (PIP2). The PIP2 is a substrate for phospholipase C which lead to the 
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production of inositol 1,4,5-triphosphate and diacylglycerol that serve as signaling 
molecules in animals. Inositol 1,4,5-triphosphate binds to specific receptors and 
induces the release of calcium from intracellular stores, while diacylglycerol 
activates protein kinase C, which in turn controls many key cellular functions, 
including differentiation, proliferation, metabolism and apoptosis (Desrivieres et al., 
1998). The PI is synthesized from the phosphatidate and the reaction involves CTP to 
produce CDP-diacylglycerol which then combines with myo-inositol to form PI and 
CMP (Berridge and Fain, 1979). 
 
1.1.2 Sphingolipids 
Sphingolipid (also known as sphingomyelin) molecules consist of a long-chain 
amino alcohol (Figure 1.2). In animals, this alcohol is known as sphingosine 
(Chaurio et al., 2009). The sphingolipid is different from phosphoglycerides because 
it does not contain glycerol backbone although they are similar in shape (Lodish et 
al., 2000). The core of each type of sphingolipid is ceramide, contain a fatty acid 
linked by an amide bond derivative of sphingosine (McKee and McKee, 2003). A 
sphingomyelin is formed by the esterification of a phosphorylcholine or a 
phosphoethanolamine to the 1-hydroxyl group of a ceramide (McKee and McKee, 
2003; Gibellini and Smith, 2010). Sphingosine-1-phosphate is a bioactive lipid and 
served as the primary precursor of ceramides which are involved as mediators of 
cellular events, for example cytoskeleton rearrangements, growth, motility and 
survival (Spiegel and Milstien, 2003). The ceramides are also precursors for the 
glycolipids (also referred to as glycosphingolipids) with an immense range of 
function in tissues (McKee and McKee, 2003). Furthermore, sphingomyelin and 
other sphingolipids together with cholesterol are located in an intimate association in  
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Figure 1.2 Core structure of sphingolipids, long chain bases form the core 
structure of sphingolipids (Rao and Acharya, 2008). 
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specific sub-domains to form lipid rafts, which appear to be associated with cellular 
signaling and the signal transduction process (Dowhan, 2009).  
 
1.2 Biosynthesis of major phospholipids in eukaryotic membranes 
The molecular basis for phospholipid function on eukaryotic systems is more 
complex and difficult than in prokaryotes. It is essential to study the roles of 
phospholipids in cell physiology and specific cellular processes (Dowhan, 1997). 
The studies for pathway of the major eukaryotic phospholipid biosynthesis were 
established mainly by Eugene Kennedy (Kennedy, 1957). Besides the study on the 
components of the cell membrane, the implication of phospholipid metabolites and 
derivatives in different mitogenic signaling pathways has also been identified 
(Gallego-Ortega et al., 2009). Figure 1.3 shows the pathways for the biosynthesis of 
major eukaryotic membrane phospholipids. 
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Figure 1.3 Pathways for the biosynthesis of major eukaryotic membrane 
phospholipids (Kent and Carman, 1999). Enzymes involved in individual steps are 
circled. CDP-choline pathway is shown in blue. PEMT pathway is shown in red. 
PLD and EK reactions are shown in black. PI and CL reactions are shown in green. 
CK, choline kinase; EK, ethanolamine kinase; CCT, choline phosphate 
cytidyltransferase; ECT, ethanolamine phosphate cytidyltransferase; CPT, choline 
phosphotransferase; EPT, ethanolamine phosphotransferase; GPAT, glycerol-3-
phosphate acyltransferase; 1 acyl-GPAT, 1 acyltransferase-GPAT; PAC, 
phosphatidate cytidyltransferase; PSS, phosphatidylserine synthase; PSD, 
phosphatidylserine decarboxylase; PEMT, phosphatidylethanolamine 
methyltransferase; PLD, phospholipase D; PIS, phosphatidylinositol synthase; PG-P 
synthase, phosphatidylglycerol phosphate synthase; PG-P phosphatase, 
phosphatidylglycerol phosphate phosphatase; CL synthase, cardiolipin  or 
diphosphatidylglycerol synthase; PA, phosphatidic acid; PS, phosphatidylserine; PC, 
phosphatidylcholine; PE, phosphatidylethanolamine; PME, 
phosphatidylmonoethanolamine; PDE, phosphatidyldiethanolamine; PI, 
phosphatidylinositol; PG, phosphatidylglycerol; CL, cardiolipin 
(diphosphatidylglycerol); CTP, Phosphocholine cytidyltransferase; DAG, 
diacylglycerol; AdoMet, S-adenosylmethionine; AdoHcy, adenosylhomocystein.  
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1.2.1 Synthesis of phosphatidic acid 
The synthesis of PA started with the acylation of glycerol-3-phosphate. The PA 
biosynthesis plays an important step in the activation of fatty acids by acyl-CoA 
synthetase to yield acyl-CoA. Five different forms of acyl-CoA synthetase have been 
identified. The synthetases function differently in the biosynthesis of phospholipid 
and triacylglycerol (TG) (Vance and Vance, 2002). The PA can be further 
hydrolyzed to the central liponucleotide intermediate, cytidine diphosphate-
diacylglycerol (CDP-DAG) via phosphatidate cytidyltransferase (PAC) (Figure 1.3), 
which is also known as CDP-DAG synthase (CDS) (Nigou and Besra, 2002). The 
CDP-DAG is a key intermediate in phospholipid synthesis in all organisms because 
of its location at the branchpoint of the biosynthetic pathway (Icho et al., 1985). The 
CDP-DAG plays a role as the donor of phosphatidyl moieties to the primary 
hydroxyl groups of serine or glycerol-3-phosphate in the generation of PI (Zuker, 
1996) or CL (Sandoval-Calderon et al., 2009), respectively (Figure 1.3). 
 
1.2.2 Synthesis of  phosphatidylcholine 
The PC biosynthetis consists of two pathways, the CDP-choline pathway (Kennedy 
pathway) and the phosphatidylethanolamine methylation (PEMT) pathway (Aoyama 
et al., 2004). The PEMT pathway predominates in yeast and fungi. For mammals, 
PEMT is significant only in mammalian liver cells for ~ 30% of hepatic PC 
biosynthesis while the CDP-choline pathway is the major route in other mammalian 
cells (Lopez-Lara and Geiger, 2001; Li and Vance, 2008).  
 
PC can be found in significant amounts in membranes of rather diverse bacteria 
especially in symbionts, pathogens and photosynthetic bacteria (Sohlenkamp et al., 
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2003; Comerci et al., 2006). The PC is constantly turned over to yield free choline 
and PA. This process is catalyzed by PLD, and the latter can be further hydrolyzed to 
DAG by the action of PA phosphatase (shown in black in Figure 1.3) (Kent and 
Carman, 1999; Zhou et al., 2000). 
 
1.2.2(a) CDP-choline pathway 
The CDP-choline pathway (shown in blue in Figure 1.3) is also known as Kennedy 
pathway, named after Eugene Kennedy who elucidated it in 1956 (Gibellini and 
Smith, 2010). The choline is mainly used for the synthesis of PC through the CDP-
choline pathway, which accounts for up to 95% of the total choline pool in most 
tissues. The remaining 5% include free choline, phosphocholine, 
glycerophosphocholine, CDP-choline and acetylcholine (Li and Vance, 2008). There 
are three reactions involved in the CDP-choline pathway. Free choline is first 
catalyzed by an enzyme choline kinase (CK), and is the first reaction of choline 
phosphorylation by ATP (Ishidate, 1997). The second reaction is the phosphocholine 
cytidylyltransferase (CCT) catalyzes the formation of CDP-choline from 
phosphocholine and CTP (Kent, 1997). The third reaction is that 
cholinephosphotransferase (CPT) catalyzes the final condensation reaction of CDP-
choline with diacylglycerol (McMaster and Bell, 1997; Vance and Vance, 2002).  
 
For the CDP-choline pathway in mammals, CK activity is the first step in 
biosynthesis, but the CCT is considered as the regulatory as well as the rate limiting 
step (Lykidis and Jackowski, 2001). However, several reports have indicated that the 
step of CK is also slow and can be a regulatory step for the net biosynthesis of PC in 
certain situations (Aoyama et al., 2004). The PC biosynthesis is also required for 
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normal very low-density lipoprotein secretion from hepatocytes. When choline 
supply is deficient, recent studies indicate that choline is recycled into the liver and 
redistributed from the kidneys, lungs (where saturated PC is an essential lipid 
component of the pulmonary surfactant), and intestines to the liver and the brain (Li 
and Vance, 2008). However, choline itself is not synthesized de novo in animal cells 
and must be obtained from dietary sources or by degradation of existing choline-
containing lipids (Ishidate, 1997).  
 
1.2.2(b) Phosphatidylethanolamine methylation pathway 
Phosphatidylethanolamine methylation (PEMT) pathway is another pathway from 
which PC can be synthesized de novo in mammalian cells (shown in red in Figure 
1.3). In mammalian cells, phospholipid N-methyltransferase catalyzes the three 
successive AdoMet-dependent methylations of phosphatidylethanolamine (Figure 1.3) 
(Watkins et al., 2003; Verkade et al., 2007). The PE used in the PEMT pathway is 
derived from PS (Kent and Carman, 1999). The PEMT is only expressed in 
significant levels in the liver and testis (Jackowski and Fagone, 2005).  
 
1.2.3 Synthesis of phosphatidylethnolamine 
The major pathway for the biosynthesis of PE in mammals is known to be a CDP-
ethanolamine pathway (Lykidis and Jackowski, 2001) which was first described by 
Kennedy and Weiss in 1956 (Vance and Vance, 2002). The CDP-ethanolamine 
pathway consists of three enzymatic steps (Figure 1.3). Firstly, ethanolamine kinase 
(EK) catalyzes the ATP-dependent phosphorylation of ethanolamine, forming 
phosphoethanolamine and the byproduct ADP. In the second step which is 
considered to be the rate-limiting step of the Kennedy pathway, it is the CTP: 
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phosphoethanolamine cytidylyltransferase (ECT) uses phosphoethanolamine and 
CTP to form the high-energy donor CDP-ethanolamine with the release of 
pyrophosphate (Leonardi et al., 2009). The final step is catalyzed by CDP-
ethanolamine: 1, 2-diacylglycerol ethanolaminephosphotransferase (EPT) using 
CDP-ethanolamine and a lipid anchor such as diacylglycerol (DAG) or alkyl-
acylglycerol (AAG) to form PE and CMP as byproducts (Bleijerveld et al., 2004). 
 
Another crucial route to synthesize PE is the decarboxylation of PS, which is 
described by Borkenhagen and colleagues (Bleijerveld et al., 2007). In this pathway, 
PS synthesized from PC or PE by phosphatidylserine-1 and -2, respectively, is 
decarboxylated by phosphatidylserine decarboxylase (PSD) to generate PE (Vance 
and Vance, 2004). To date, only one mammalian PSD has been cloned, and it was 
shown to be active in mitochondria (Vermeulen et al., 1997; Bleijerveld et al., 2007). 
 
1.2.4 Synthesis of phosphatidylserine 
PS is made in prokaryotes, some plants and in yeasts through the CDP-diacylglycerol 
pathway. However this pathway does not exist in mammalian cells. Instead, PS is 
synthesized by a base-exchange reaction, in which the head group of a PC or PE is 
exchanged for L-serine (Vance and Vance, 2002; Moldave, 2003). This pathway was 
first described by Hubscher in 1959 (Vance and Vance, 2002). The PS is synthesized 
by two distinct PS synthases, PS synthase-1 (PSS1) and PS synthase-2 (PSS2) 
(Arikketh et al., 2008). The PSS1 exchanges serine for the choline head group of PC, 
while PSS2 uses PE as a substrate (Vance and Steenbergen, 2005). 
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1.3 Choline kinase 
Dietary choline is an essential nutrient which is absorbed by the intestine in the form 
of lysophosphatidylcholine and choline, and, the uptake by the cell is carried out 
either by passive diffusion or diffusion facilitated by specific choline transporters 
(Michel et al., 2006; Li and Vance, 2008). Upon entry into the cell, the choline is 
immediately phosphorylated to phosphocholine or oxidized to betaine. These 
processes take place mainly in hepatocytes (Katz-Brull et al., 2002). The 
phosphorylation of choline is catalyzed by choline kinase (CK) which constitutes the 
first step of Kennedy pathway (Ishidate, 1997). 
 
The enzymatic reaction of CK in Brewer’s yeast was first described by Wittenberg 
and Kornberg in 1953 (Wittenberg and Kornberg, 1953). In human, CK (ATP: 
choline phosphotransferase, EC 2.7.1.32) (Aoyama et al., 2000) is encoded by two 
separate genes, CKA and CKB, located on chromosomes 11q13.2 and 23q13.33, 
respectively (Gallego-Ortega et al., 2011). Alternative splicing of the CKA transcript 
results in two functional isoforms, CKα1 and CKα2; CKB encodes CKβ (Wu and 
Vance, 2010). CKα1 has 457 amino acids while CKα2 has 439 amino acids. They are 
only different in an additional stretch of 18 amino acids that begin at the position 155. 
CKβ has 395 amino acids and its sequence is approximately 40% different from 
CKα1 and CKα2 (Gallego-Ortega et al., 2011). Active CK has been proposed to 
consist of either homo- or hetero-dimeric (oligomeric) forms, and neither isoform is 
active in its monomeric form (Liao et al., 2006).  
 
Nowadays, different cDNAs of CK from yeasts, mammals and plants have been 
cloned and characterized (Strausberg et al., 2002; Kent, 2005). The CK also carries 
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the Ethanolamine Kinase activity in several organisms and has been reported to be 
involved in the synthesis of PE using ethanolamine as substrate to produce 
phosphoethanolamine (Aoyama et al., 2000; Gallego-Ortega et al., 2011). 
Furthermore, CK is a vital protein that involves in cancer, and the specific 
interference with the CK activity constitutes a new efficient strategy for cancer 
treatment (Ramirez de Molina et al., 2004b). 
 
In mammals, the CK cDNA was first obtained from a rat liver λgt11 library by 
screening using the antibody against rat liver CK. The open reading frame encoded 
435 amino acids with a molecular mass of 49743 Da (Uchida and Yamashita, 1992). 
Later, the liver enzyme was found to exist in two isozymes, termed CKRI and CKRII 
(Porter and Kent, 1990). The 5’ region of the CKR gene exhibited the features of not 
only a housekeeping gene but also of a gene regulated via a variety of putative cis-
acting elements (Uchida, 1994).  
 
1.3.1 Biochemical characteristic of choline kinase isoforms 
Recently, the enzymatic properties of CKα1 and CKβ have been characterized in 
vitro and in vivo (Gallego-Ortega et al., 2011). In vitro, the Michaelis constant (Km) 
of CKβ for choline was higher than CKα1 while the Km of CKβ for ethanolamine 
was lower than CKα1. In vivo, CKβ showed only an EK role while CKα1 displayed 
both CK/EK roles, suggesting that each CK isoform plays distinct role in 
biochemical pathways under in vivo conditions and behave differently in vitro 
(Gallego-Ortega et al., 2009; Gallego-Ortega et al., 2011). 
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Homozygosity for the mutant CKα mice are lethal in embryonic stage (Wu et al., 
2008) whereas mice with a knocked-out CKβ are viable to the adult stage but causes 
rostrocaudal muscular dystrophy (rmd) and bone deformities (Sher et al., 2006; Wu 
et al., 2009; Wu et al., 2010). The rmd mice show normal PC levels in all tissues 
except in skeletal muscle of the forelimbs with an unusual rostral-to-caudal gradient 
(Sher et al., 2006). The heterozygous mutant of CKα mice appeared normal in 
embryonic development and gross anatomy and was fertile (Wu et al., 2008). It 
suggests that CKα plays a crucial role under physiological conditions but CKβ is 
insufficient to compensate the PC biosynthesis or even to provide the minimal 
requirements of phosphocholine (Gallego-Ortega et al., 2011). In addition, 
heterozygous CKα knockout mice showed decreased PE levels (Wu et al., 2008). 
This suggests that there is a dual role for the CKα isoform in the biosynthesis of PC 
and PE (Gallego-Ortega et al., 2011). 
 
In humans, disruption of PC synthesis by loss of function due to mutation of CKβ 
activity in muscle causes congenital muscular dystrophy (CMD) (Mitsuhashi et al., 
2011a; Mitsuhashi et al., 2011b). The feature of the muscle pathology in humans and 
mice is characterized by distinct mitochondrial morphological abnormalities where 
mitochondria were absent in the center of muscle fibers and significantly enlarged at 
the periphery (Sher et al., 2006; Wu et al., 2010; Mitsuhashi et al., 2011a). PC levels 
are significantly decreased and CK activity is absent in the skeletal muscle from 
CMD human and rmd mice. However, in other tissues, where there was only a mild 
decrease in CK activity, PC levels are not altered and there are no obvious 
pathological changes. This is supported by the fact that CKα was not detected in 
muscle (Mitsuhashi et al., 2011b). Furthermore, loss of function through mutation of 
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CKβ causes mitochondria to be abnormally large and exhibit decreased inner 
membrane potential in hindlimb muscle of mice whereas presence of mega 
mitochondria was in insignificant amounts in forelimb muscle and functioned 
normally. Hence, the distinction in forelimb versus hindlimb muscle of CKβ 
deficient mice is predominantly due to CKα, but less contribution of CKβ, to total 
CK activity in forelimb muscle (Wu et al., 2010).  
 
1.4 Choline kinase in cell transformation and carcinogenesis 
Overexpression of CK, which leads to higher level of phosphocholine can potentially 
lead to carcinogenesis. CK is suggested to be involved in the ras signaling pathway 
mediated by the ras oncogene (Ramirez de Molina et al., 2004b). There are two well 
known ras oncogene effectors, PI3K and Ral-GDS (Ramirez de Molina et al., 
2002a). Several ras oncogenes such as src, raf and mos could also increase the 
endogenous CK activity and phosphocholine level when expressed in the murine 
fibroblasts (Ratnam and Kent, 1995; Hernandez-Alcoceba et al., 1997; Ramirez de 
Molina et al., 2001). 
 
Production of phosphocholine also plays an essential role in cell growth that are 
induced by growth factors both in murine fibroblasts (Kiss and Chung, 1996) and in 
different human cells. Treatment of human cells with growth factors such as EGF, 
PDGF or HRG results in blockage of DNA synthesis. The increase in growth factors 
induced the production of phosphorylcholine (Ramirez de Molina et al., 2004a).  
 
Interestingly, the elevated phosphocholine levels appear to be a common 
characteristic feature in cell lines derived from human tumors (Bhakoo et al., 1996). 
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The elevation of phosphocholine level which is associated to cell malignancy is 
detected by nuclear magnetic resonance (NMR). It has been demonstrated that 
different tumors in murine and human, showed increased levels of phosphocholine 
compared to their corresponding normal tissues (Podo et al., 2007). Phosphocholine 
as a malignancy marker, such as a biomarker for breast cancer, is useful for the 
diagnostic and monitoring of the cancer’s progression (Eliyahu et al., 2007). 
 
CK generates phosphocholine in the carcinogenic process and it has been found that 
CK activity was increased in tissues from human tumors (Glunde et al., 2005; 
Eliyahu et al., 2007; Iorio et al., 2010). Human CK, expressed in murine fibroblast, 
increases DNA synthesis when stimulated by insulin, insulin-like growth factor I 
(IGF-I) and other growth factors (Chung et al., 2000). The overexpression of CK in 
primary human mammary epithelial cells was sufficient for growth factor-induced 
proliferation because its overexpression causes an increase in DNA synthesis 
(Ramirez de Molina et al., 2004a). Furthermore, high levels of CK mRNA have been 
detected in colon cancer induced by 1,2-dimethylhydrazine (DMH) in rats 
(Nakagami et al., 1999a) as well as in tumors induced by polycylic aromatic 
hydrocarbons (PAHs) (Mordukhovich et al., 2010). Besides, carbon tetrachloride 
(CCl4) was also induced CK activity 2-4 fold (Aoyama et al., 2002). 
 
Most of the studies have reported that CKα is overexpressed in a variety of cell lines 
derived from human tumors such as in breast, prostate, colon, brain, lung, bladder 
and cervix carcinoma tumor tissues (Banez-Coronel et al., 2008; Nimmagadda et al., 
2009; Shah et al., 2010) but there is no evidence that reports overexpression of CKβ 
in the carcinogenesis process (Gallego-Ortega et al., 2009). The induction of CKα 
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activity in these types of cancer ranges from 40% to 60% (Gallego-Ortega et al., 
2006). Furthermore, a study using 167 tumor samples showed that non-small cell 
lung cancer (NSCLC) patients with an overexpression of CKα had a worse survival 
rate compared to those who did not, and this could entail important clinical 
consequences (Ramirez de Molina et al., 2007). Recently, overexpression of CKα1 
has been shown to increase invasiveness in human breast cancer as well as resistance 
to treatment with 5-fluorouracil (5-FU) (Shah et al., 2010). 
 
Recenly, the implication of CKβ in cell transformation and human carcinogenesis 
both in vitro and in vivo has been discovered. However, the effect of CKβ 
overexpression on cell transformation is still not very clear. Overexpression of CKβ 
had no significant effect on the number or the size of the cancer cell colonies. In 
addition, CKβ was unable to induce tumor growth under conditions where CKα1 
does (Ramirez de Molina et al., 2005; Gallego-Ortega et al., 2009). 
 
In gene expression profiling, mRNA of CKα1 shows significant overexpression in a 
panel of breast, lung and ovarian cancer cell lines when compared with their normal 
counterparts whereas no changes were found for CKβ mRNA levels (Eliyahu et al., 
2007; Gallego-Ortega et al., 2009; Iorio et al., 2010). These findings are important as 
the overexpression of CKα1 activity is able to transform cells from different origins 
(Ramirez de Molina et al., 2005; Gallego-Ortega et al., 2009; Gallego-Ortega et al., 
2011). Most of the findings suggest that CKα is involved in the cell growth 
regulation and is altered during the carcinogenic process, hence development of new 
families of anticancer drugs to inhibit CKα activity may provide a novel cancer 
therapeutic strategy (Aoyama et al., 2004). 
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1.5 Promoter 
A promoter is a DNA sequence which is directly upstream to the coding sequence 
that regulates transcription of a gene. Gene transcription is regulated by the binding 
of transcription factors specifically to the regions of the promoter (Xuan et al., 2005). 
Promoters are the best-characterized transcriptional regulatory sequences in complex 
genomes because of their predictable location upstream of transcriptional start site 
(TSS). Promoters consist of two separate segments, the core (proximal) and the 
extended (distal) regions.  
 
The core promoter is normally located within 50 bp of the TSS, where the 
preinitiation complex forms and the general transcription machinery assembles 
(Cooper et al., 2006). The core promoter elements appear to interact directly with the 
RNA polymerase II, which is essential to begin the transcription. Most of the studies 
of the basal machinery have been performed with promoters that consist of the 
TATA box as an essential element (Smale and Kadonaga, 2003). However, the 
specific regulatory sequences that control spatial and temporal expression of the 
downstream gene are present in the extended (distal) promoter. Since promoters 
consists of many classes of eukaryotic transcriptional regulatory elements, hence 
identification and characterization of these elements are important to understand the 
complex network of human gene regulation (Cooper et al., 2006). 
 
1.5.1 Transcription factors 
A transcription factor is a protein which acts by binding to a specific short DNA 
sequence that in turn regulates the gene transcription either positively or negatively 
(Latchman, 1997). Transcription factors are important for the regulation of gene 
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expression. Transcription factors are found in all living organisms and the number of 
transcription factors present within an organism increases with the genome size (van 
Nimwegen, 2003). In the human genome, there are approximately 2600 proteins that 
contain DNA binding domains and most of these are presumed to function as 
transcription factors (Babu et al., 2004).  
 
The transcription of a gene is regulated by trans-acting protein factors that interact 
with specific cis-acting elements (Schwemmle et al., 1997). Transcription of an 
eukaryotic protein-coding gene is preceded by several events, such as locus 
decondensation, remodeling of the nucleosome, histone modifications, the binding of 
transcriptional activators and coactivators to enhancers, and recruitment of the basal 
transcription machinery to the core promoter (Smale and Kadonaga, 2003). However, 
only a few nucleotides are significant in its function within a promoter (Baliga, 2001). 
 
Eukaryotic transcription factors can be categorized into various families on the basis 
of conserved sequences among their DNA-binding domains (Table 1.2). Several 
distinct trans-acting factors normally interact with a common binding site due to such 
structural conservation. Furthermore, some findings indicate that the interaction of 
distinct transcription factors with a common target site does not essentially result in 
similar transcriptional responses. Hence, some factors may activate the transcription,  
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Table 1.2 Some major transcription factor families and functions 
Family Representative 
transcription factors 
Some functions 
basic leucine zipper 
(bZIP) 
AP-1, CREB (Cha-
Molstad et al., 2004; Cai 
et al., 2008)  
Liver differentiation, fat cell 
specification (Gilbert, 2000) 
basic helix-loop-helix 
(bHLH) 
SRY, AhR/Ar, USF  
(Luo and Sawadogo, 
1996; Bhandari et al., 
2011; Pocar et al., 2005) 
Sex-determination, 
carcinogenesis (Ledent and 
Vervoort, 2001; Gilbert, 2000) 
zinc finger  GATA, MZF1, Sp1, Ik  Carcinogenesis, expressed in 
hematopoietic progenitors 
including erythroid cells (Gaboli 
et al., 2001; Viger et al., 2008; 
Deniaud et al., 2006; Dijon et 
al., 2008) 
Rel homology NF-kappa Human diseases (Ahn and 
Aggarwal, 2005) 
winged helix-turn-
helix (wHTH) 
E2F, ETS, HSF, Elk-1 Carcinogenesis, response to 
various stresses, (Donaldson et 
al., 1996; Hashikawa et al., 
2006) 
grainyhead-related 
protein 
CP2 (To et al., 2010) Erythroid gene expression 
(Kokoszynska et al., 2008) 
 
